Asahi Kasei Reports the Acquisition of Calliditas Therapeutics for an Aggregate of ~$1.11B
Shots:
- Asahi Kasei has agreed to acquire Calliditas Therapeutics, aiming to make it a wholly-owned subsidiary. The offer includes acquiring all the ordinary shares and American Depositary Shares (ADS), each representing two Calliditas shares
- Under the agreement, Asahi Kasei will acquire Calliditas’ ordinary shares listed on Nasdaq Stockholm for ~$19.59 per unit and American Depositary Shares of Calliditas listed on Nasdaq Global Select Market for ~$39.17 per unit, making it an aggregate of ~$1.11B
- Through the acquisition, Asahi Kasei intends to expand its in-house sales structure for renal and autoimmune diseases across the US, establish a European presence focusing on R&D as well as broaden in-licensing and new drug development
Ref: Asahi Kasei | Image: Asahi Kasei
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
